Together, cancer meets its match
Omico is a government-backed national network of leading researchers, clinicians and industry partners that’s using precision medicine to unlock new potential in Australian research and turn the tide on cancer. With fast-tracked molecular screening, biomarker-led trial set up and patient enrolment from the entire nation we’re accelerating access to next-generation treatments and preventive strategies, improving outcomes for all Australians affected by cancer.
What we do
Omico is…
- Promoting precision medicine, a game changer in the fight against cancer
- Uniting Australia’s world-class cancer institutes, researchers, industry partners and government like never before
- Providing free molecular screening to 25,000 Australians with cancer to match them to innovative new treatments in clinical trials
How our molecular screening works
If you or someone you know has advanced or incurable cancer or is at high-risk for cancer (due to hereditary conditions) then:
- Your doctor completes an online referral form
- You sign a consent form
- Omico assesses the genes and other molecules in your cancer tissue
- Our experts match results to an existing therapy or clinical trial of a new drug
- Process takes 8 to 10 weeks
Researchers
Meet intellectually-stimulating research that changes cancer care and transforms lives.
Clinicians
Meet accelerated access to innovative new therapies for your patients.
Government
Meet an opportunity to advance the nation’s health and wealth.
Advocacy Groups
Meet a partner that can help you make a real difference for those affected by cancer.
Who we work with
Recent news
PrOSPeCT formally launches, bringing new hope to Australians with incurable or advanced cancers
Pioneering national genomics initiative gives 23,000 Australians their best fighting chance against the toughest cancers
7,000 patients reached via MoST
As of March 2023, we have screened more than 7,000 patients through our Molecular Screening & Therapeutics (MoST) study.
Ground-breaking Australian research answers long-standing genetic mystery of why people develop rare hidden cancer
Research led by Omico, the Garvan Institute of Medical Research and UNSW Sydney has generated the first comprehensive genetic map of sarcomas, identifying several new important genes that when inherited can cause this deadly cancer. The research has wide implications for people living with sarcoma and their families – allowing detection of the cancer earlier and potentially improving survival for patients.